Posted by Michael Wonder on 03 Aug 2020
Novartis Cosentyx receives EU approval for first-line systemic treatment in paediatric psoriasis
3 August 2020 - EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile.
Novartis today announced the European Commission has granted the approval for Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years.
The recommended dose for children up to 50 kg is 75 mg (without a lower weight restriction), and 150 mg for children 50 kg and over (150 mg as a starting dose, which may be increased to 300 mg, if needed).
